Damora Therapeutics启动Dmr-001治疗突变CALR驱动型原发性血小板增多症与骨髓纤维化的Clarity-101 1/1B期临床试验

美股速递
Aug 05

Damora Therapeutics正式启动一项名为Clarity-101的1/1B期临床试验,旨在评估其候选药物Dmr-001在突变型钙网蛋白驱动的原发性血小板增多症及骨髓纤维化患者中的疗效与安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10